Combined Targeted Therapies for Triple Negative Advanced Breast Cancer A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib.

Trial Profile

Combined Targeted Therapies for Triple Negative Advanced Breast Cancer A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 May 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Erlotinib (Primary) ; Paclitaxel (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 May 2017 Planned primary completion date changed from 1 Apr 2017 to 2 Mar 2018.
    • 06 Jan 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top